CY1124037T1 - Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης - Google Patents
Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσηςInfo
- Publication number
- CY1124037T1 CY1124037T1 CY20201101050T CY201101050T CY1124037T1 CY 1124037 T1 CY1124037 T1 CY 1124037T1 CY 20201101050 T CY20201101050 T CY 20201101050T CY 201101050 T CY201101050 T CY 201101050T CY 1124037 T1 CY1124037 T1 CY 1124037T1
- Authority
- CY
- Cyprus
- Prior art keywords
- preparation
- microspherds
- controlled release
- release characteristics
- peptide loaded
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/000858 WO2015149820A1 (en) | 2014-03-31 | 2014-03-31 | Preparation of peptide loaded plga microspheres with controlled release characteristics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124037T1 true CY1124037T1 (el) | 2022-03-24 |
Family
ID=50486884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101050T CY1124037T1 (el) | 2014-03-31 | 2020-11-09 | Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9943483B2 (enExample) |
| EP (1) | EP3125871B1 (enExample) |
| JP (1) | JP6494657B2 (enExample) |
| KR (1) | KR102218655B1 (enExample) |
| CN (2) | CN114191538A (enExample) |
| AU (1) | AU2014389015B2 (enExample) |
| BR (1) | BR112016022550B1 (enExample) |
| CA (1) | CA2944561C (enExample) |
| CY (1) | CY1124037T1 (enExample) |
| DK (1) | DK3125871T3 (enExample) |
| EA (1) | EA032580B1 (enExample) |
| ES (1) | ES2837044T3 (enExample) |
| HR (1) | HRP20210058T1 (enExample) |
| HU (1) | HUE052289T2 (enExample) |
| LT (1) | LT3125871T (enExample) |
| MX (1) | MX371139B (enExample) |
| PL (1) | PL3125871T3 (enExample) |
| PT (1) | PT3125871T (enExample) |
| RS (1) | RS61209B1 (enExample) |
| SI (1) | SI3125871T1 (enExample) |
| SM (1) | SMT202000692T1 (enExample) |
| WO (1) | WO2015149820A1 (enExample) |
| ZA (1) | ZA201607413B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2928500B1 (en) | 2012-12-04 | 2019-03-06 | Phosphorex Inc. | Microparticles and nanoparticles having negative surface charges |
| CN107106499B (zh) * | 2014-11-02 | 2021-09-17 | 纳诺精密医疗有限公司 | 用于延长释放治疗剂的可植入医药装置 |
| US20230022463A1 (en) * | 2014-11-02 | 2023-01-26 | Nano Precision Medical, Inc. | Implantable medical devices for extended release of therapeutic agents |
| KR102068578B1 (ko) * | 2016-08-16 | 2020-01-21 | 중앙대학교 산학협력단 | 세포전달을 위한 다공성 마이크로스피어 및 이의 제조방법 |
| EP3551575A4 (en) * | 2016-12-12 | 2020-08-12 | Phosphorex, Inc. | MICROPARTICLE AND NANOPARTICLE WITH NEGATIVE SURFACE CHARGES |
| CN108113975B (zh) * | 2018-02-02 | 2020-10-09 | 中国人民解放军军事科学院军事医学研究院 | 一种基于涡漩振荡器的plga微球制备方法及其应用 |
| KR101936040B1 (ko) * | 2018-04-23 | 2019-01-08 | 주식회사 씨트리 | 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법 |
| CN109106688B (zh) * | 2018-08-22 | 2021-08-17 | 丽珠医药集团股份有限公司 | 一种醋酸奥曲肽微球的制备方法 |
| KR102181231B1 (ko) * | 2018-11-22 | 2020-11-20 | 주식회사 메디포럼제약 | 로티고틴 함유 고분자 미립자의 제조방법 |
| JP7600528B2 (ja) * | 2020-03-16 | 2024-12-17 | 株式会社リコー | 粒子の製造方法 |
| JP6810502B1 (ja) * | 2020-05-08 | 2021-01-06 | エム・テクニック株式会社 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
| KR20220163417A (ko) * | 2020-05-08 | 2022-12-09 | 엠. 테크닉 가부시키가이샤 | 주제가 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제 |
| KR20220163418A (ko) * | 2020-05-08 | 2022-12-09 | 엠. 테크닉 가부시키가이샤 | 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제 |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| CN116139256A (zh) * | 2023-03-14 | 2023-05-23 | 复旦大学附属肿瘤医院 | 生长抑素/生长抑素类似物缓释膜及其制备方法和应用 |
| CN120919405B (zh) * | 2025-10-14 | 2025-12-16 | 渼颜空间生物科技(吉林)有限公司 | 一种pha微球、及其制备方法、含其制剂和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| US6913767B1 (en) * | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
| US6902743B1 (en) * | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
| WO2001010414A1 (en) * | 1999-08-04 | 2001-02-15 | Oakwood Laboratories L.L.C. | Slow release microspheres |
| EP1742616B1 (en) * | 2004-04-30 | 2014-10-01 | Abraxis BioScience, LLC | Sustained-release microspheres and methods of making and using same |
| US20100086597A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide with a low initial burst |
| US20100086596A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for releasing an octreotide compound without an initial time lag |
| US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
-
2014
- 2014-03-31 LT LTEP14717411.4T patent/LT3125871T/lt unknown
- 2014-03-31 EA EA201691884A patent/EA032580B1/ru unknown
- 2014-03-31 DK DK14717411.4T patent/DK3125871T3/da active
- 2014-03-31 WO PCT/EP2014/000858 patent/WO2015149820A1/en not_active Ceased
- 2014-03-31 HU HUE14717411A patent/HUE052289T2/hu unknown
- 2014-03-31 US US15/124,587 patent/US9943483B2/en active Active
- 2014-03-31 CN CN202111524730.8A patent/CN114191538A/zh active Pending
- 2014-03-31 ES ES14717411T patent/ES2837044T3/es active Active
- 2014-03-31 HR HRP20210058TT patent/HRP20210058T1/hr unknown
- 2014-03-31 EP EP14717411.4A patent/EP3125871B1/en active Active
- 2014-03-31 KR KR1020167029649A patent/KR102218655B1/ko active Active
- 2014-03-31 BR BR112016022550-3A patent/BR112016022550B1/pt active IP Right Grant
- 2014-03-31 MX MX2016012846A patent/MX371139B/es active IP Right Grant
- 2014-03-31 PL PL14717411T patent/PL3125871T3/pl unknown
- 2014-03-31 PT PT147174114T patent/PT3125871T/pt unknown
- 2014-03-31 AU AU2014389015A patent/AU2014389015B2/en active Active
- 2014-03-31 SM SM20200692T patent/SMT202000692T1/it unknown
- 2014-03-31 SI SI201431746T patent/SI3125871T1/sl unknown
- 2014-03-31 RS RS20201537A patent/RS61209B1/sr unknown
- 2014-03-31 CN CN201480077756.4A patent/CN106170284A/zh active Pending
- 2014-03-31 JP JP2016559649A patent/JP6494657B2/ja active Active
- 2014-03-31 CA CA2944561A patent/CA2944561C/en active Active
-
2016
- 2016-10-27 ZA ZA2016/07413A patent/ZA201607413B/en unknown
-
2020
- 2020-11-09 CY CY20201101050T patent/CY1124037T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016022550B1 (pt) | 2023-03-28 |
| EP3125871B1 (en) | 2020-10-21 |
| JP6494657B2 (ja) | 2019-04-03 |
| CN106170284A (zh) | 2016-11-30 |
| EA201691884A1 (ru) | 2017-02-28 |
| KR102218655B1 (ko) | 2021-02-22 |
| US9943483B2 (en) | 2018-04-17 |
| BR112016022550A2 (enExample) | 2017-08-15 |
| ES2837044T3 (es) | 2021-06-29 |
| CA2944561A1 (en) | 2015-10-08 |
| HUE052289T2 (hu) | 2021-04-28 |
| SI3125871T1 (sl) | 2021-03-31 |
| AU2014389015A1 (en) | 2016-09-29 |
| EP3125871A1 (en) | 2017-02-08 |
| ZA201607413B (en) | 2018-11-28 |
| CN114191538A (zh) | 2022-03-18 |
| US20170281547A1 (en) | 2017-10-05 |
| CA2944561C (en) | 2019-06-18 |
| MX371139B (es) | 2020-01-20 |
| EA032580B1 (ru) | 2019-06-28 |
| RS61209B1 (sr) | 2021-01-29 |
| LT3125871T (lt) | 2020-12-28 |
| HRP20210058T1 (hr) | 2021-03-05 |
| WO2015149820A1 (en) | 2015-10-08 |
| JP2017509661A (ja) | 2017-04-06 |
| PL3125871T3 (pl) | 2021-04-19 |
| KR20160137608A (ko) | 2016-11-30 |
| SMT202000692T1 (it) | 2021-01-05 |
| AU2014389015B2 (en) | 2019-05-09 |
| DK3125871T3 (da) | 2020-12-21 |
| PT3125871T (pt) | 2021-01-06 |
| MX2016012846A (es) | 2017-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124037T1 (el) | Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης | |
| NI201800038S (es) | Dispositivo de administración de medicamento intranasal | |
| CY1123720T1 (el) | Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος | |
| CL2014003215A1 (es) | Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion | |
| CL2014003216A1 (es) | Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion. | |
| MX2021000174A (es) | Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos. | |
| IL269452A (en) | Syringe pumps for automatic drug compounders | |
| IL256363A (en) | Cellular targeted active ingredient delivery system | |
| SI3256138T1 (sl) | Farmacevtski sestavki, ki obsegajo meloksikam | |
| ZA201800960B (en) | Compositions with permeation enhancers for drug delivery | |
| IL254813A0 (en) | Sustained-release injectable formulations containing isoxazoline active agent and methods and uses thereof | |
| CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
| DK3236943T3 (da) | Sammensætninger til ileo-jejunal lægemiddeladministration | |
| DK3357491T3 (da) | Farmaceutisk sammensætning til afgivelse af et anionisk medikament | |
| CU20160164A7 (es) | Un nanocomplejo micelar | |
| HUE054551T2 (hu) | Ösztetrolt tartalmazó, szájban diszpergálódó tabletta | |
| MX373189B (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación. | |
| DK3310800T3 (da) | Leveringssystem til styret lægemiddelfrigivelse | |
| EP2968162A4 (en) | Multi-stage biodegradable drug delivery platform | |
| PH12016501841A1 (en) | Immunosuppressant formulation | |
| CY1122578T1 (el) | Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα | |
| CY1123022T1 (el) | Σταθερες φαρμακευτικες συνθεσεις που περιεχουν σιταγλιπτινη υπο τη μορφη δισκιων αμεσης απελευθερωσης | |
| BR112016016297A2 (pt) | Aparelho para cortar um polímero superabsorvente, e método para preparar um polímero superabsorvente | |
| EP3658123A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD | |
| EP3612231C0 (en) | DRUG DELIVERY SYSTEM |